Skip to content

A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy

A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05828875
Enrollment
1000
Registered
2023-04-25
Start date
2023-08-01
Completion date
2024-07-01
Last updated
2023-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival

Brief summary

This study is a multicenter cross-sectional survey of esophageal cancer patients who underwent radical chemoradiotherapy/radiotherapy from July 2017 to July 2020 in various medical centers, and who survived without disease progression at the time of the survey. The purpose of this study is to evaluate the current quality of life, as well as the incidence of long-term toxic side effects, nutritional status, and psychological status of esophageal cancer patients cured by radiotherapy.

Interventions

Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology

Sponsors

Tianjin Medical University Cancer Institute and Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Voluntarily accept this survey and research; * The age at the time of radiotherapy is between 18-75 years old, and the age at the time of investigation is\<80 years old; * Histologically confirmed esophageal squamous cell carcinoma without undergoing surgical resection; * Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020, currently alive and without disease progression; * Radiotherapy dose ≥ 45Gy.

Exclusion criteria

* Patients who do not cooperate with this survey; * Patients who have died at the time of investigation; * Patients who experience tumor progression within the time frame from the end of radiotherapy to receiving this survey; * Patients diagnosed with other malignant tumors within the time frame from the end of radiotherapy to receiving this survey; * Patients with incorrect contact information and missing visits

Design outcomes

Primary

MeasureTime frame
Quality of Life Assessment surveyTwo years after the end of radiotherapy

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026